Isthmus Partners Lowers stake in Becton Dickinson and Co (BDX)

Becton Dickinson and Co (BDX) : Isthmus Partners reduced its stake in Becton Dickinson and Co by 3.73% during the most recent quarter end. The investment management company now holds a total of 41,043 shares of Becton Dickinson and Co which is valued at $7,252,709 after selling 1,589 shares in Becton Dickinson and Co , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Becton Dickinson and Co makes up approximately 2.27% of Isthmus Partners’s portfolio.

Other Hedge Funds, Including , Dekabank Deutsche Girozentrale reduced its stake in BDX by selling 2,902 shares or 6.05% in the most recent quarter. The Hedge Fund company now holds 45,092 shares of BDX which is valued at $7,833,833. Becton Dickinson and Co makes up approx 0.08% of Dekabank Deutsche Girozentrale’s portfolio.Concert Wealth Management reduced its stake in BDX by selling 471 shares or 4.4% in the most recent quarter. The Hedge Fund company now holds 10,230 shares of BDX which is valued at $1,800,480. Becton Dickinson and Co makes up approx 0.24% of Concert Wealth Management’s portfolio. High Point Bank Trust Co sold out all of its stake in BDX during the most recent quarter. The investment firm sold 500 shares of BDX which is valued $87,265.

Becton Dickinson and Co opened for trading at $174.32 and hit $175.29 on the upside on Monday, eventually ending the session at $174.21, with a gain of 0.13% or 0.23 points. The heightened volatility saw the trading volume jump to 5,26,567 shares. Company has a market cap of $37,094 M.

On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.

Investors should note that on Jul 26, 2016, Becton Dickinson and Co announced a cash dividend of $0.6600. The company’s management has announced Sep 7, 2016 as the ex-dividend date and fixed the record date on Sep 9, 2016. The payable date has been fixed on Sep 30, 2016.

Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.

Leave a Reply

Becton Dickinson and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Becton Dickinson and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.